Best Practice & Research Clinical Endocrinology & Metabolism
Volume 22, Issue 4 , Pages 573-585 , August 2008

Exogenous and endogenous hormones and breast cancer

  • Wendy Y. Chen, MD, MPH (Doctor)

      Affiliations

    • Corresponding Author InformationTel.: +1 617 525 2225; Fax: +1 617 525 2008.

References 

  1. Beatson GT. On the treatment of inoperable cases of carcinoma of the mamma: suggestions for a new method of treatment, with illustrative cases. Lancet. July 11, 1896;148(3802):104–107
  2. Pike MC, Karilo M, Henderson BE, et al. ‘Hormonal’ risk factors, ‘breast tissue age’ and the age-incidence of breast cancer. Nature. 1983;303:767–770
  3. Ravdin PM, Cronin KA, Howlader N, et al. The decrease in breast-cancer incidence in 2003 in the United States. The New England Journal of Medicine. Apr 19 2007;356(16):1670–1674
  4. Beral V. Breast cancer and hormone-replacement therapy in the million women study. Lancet. Aug 9 2003;362(9382):419–427
  5. Hersh AL, Stefanick ML, Stafford RS. National use of postmenopausal hormone therapy: annual trends and response to recent evidence. The Journal of the American Medical Association. Jan 7 2004;291(1):47–53
  6. Watson J, Wise L, Green J. Prescribing of hormone therapy for menopause, tibolone, and bisphosphonates in women in the UK between 1991 and 2005. European Journal of Clinical Pharmacology. Sep 2007;63(9):843–849
  7. Faber A, Bouvy ML, Loskamp L, et al. Dramatic change in prescribing of hormone replacement therapy in the Netherlands after publication of the Million Women Study: a follow-up study. British Journal of Clinical Pharmacology. Dec 2005;60(6):641–647
  8. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. The Journal of the American Medical Association. 2002;288(3):321–333
  9. Anderson GL, Limacher M, Assaf AR, et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. The Journal of the American Medical Association. Apr 14 2004;291(14):1701–1712
  10. Chlebowski RT, Hendrix SL, Langer RD, et al. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative randomized trial. The Journal of the American Medical Association. Jun 25 2003;289(24):3243–3253
  11. McTiernan A, Martin CF, Peck JD, et al. Estrogen-plus-progestin use and mammographic density in postmenopausal women: Women's Health Initiative randomized trial. Journal of the National Cancer Institute. Sep 21 2005;97(18):1366–1376
  12. Stefanick ML, Anderson GL, Margolis KL, et al. Effects of conjugated equine estrogens on breast cancer and mammography screening in postmenopausal women with hysterectomy. The Journal of the American Medical Association. Apr 12 2006;295(14):1647–1657
  13. Collaborative group on hormonal factors in breast cancer. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. [see comments] [published erratum appears in Lancet 1997 Nov 15;350(9089):1484] Lancet. 1997;350(9084):1047–1059
  14. American College of Obstetricians and Gynecologists Women's Health Care Physicians. Executive summary. Hormone therapy. Obstetrics and Gynecology. Oct 2004;104(4 Suppl):1S–4S
  15. U.S. Preventive Services Task Force. Hormone therapy for the prevention of chronic conditions in postmenopausal women: recommendations from the U.S. preventive services task force. Annals of Internal Medicine. May 17 2005;142(10):855–860
  16. Vassilopoulou-Sellin R, Cohen DS, Hortobagyi GN, et al. Estrogen replacement therapy for menopausal women with a history of breast carcinoma: results of a 5-year, prospective study. Cancer. Nov 1 2002;95(9):1817–1826
  17. von Schoultz E, Rutqvist LE. Menopausal hormone therapy after breast cancer: the Stockholm randomized trial. Journal of the National Cancer Institute. Apr 6 2005;97(7):533–535
  18. Holmberg L, Iversen OE, Rudenstam CM, et al. Increased risk of recurrence after hormone replacement therapy in breast cancer survivors. Journal of the National Cancer Institute. 2008;100:475–482
  19. Graham JD, Clarke CL. Physiological action of progesterone in target tissues. Endocrine Reviews. Aug 1997;18(4):502–519
  20. Chen WY, Manson JE, Hankinson SE, et al. Unopposed estrogen therapy and the risk of invasive breast cancer. Archives of Internal Medicine. May 8 2006;166(9):1027–1032
  21. Chen WY, Colditz GA. Risk factors and hormone-receptor status: epidemiology, risk-prediction models and treatment implications for breast cancer. Nature Clinical Practice. Oncology. Jul 2007;4(7):415–423
  22. Stahlberg C, Pedersen AT, Lynge E, et al. Increased risk of breast cancer following different regimens of hormone replacement therapy frequently used in Europe. International Journal of Cancer. May 1 2004;109(5):721–727
  23. Fournier A, Berrino F, Clavel-Chapelon F. Unequal risks for breast cancer associated with different hormone replacement therapies: results from the E3N cohort study. Breast Cancer Research and Treatment. Jan 2008;107(1):103–111
  24. Tamimi RM, Hankinson SE, Chen WY, et al. Combined estrogen and testosterone use and risk of breast cancer in postmenopausal women. Archives of Internal Medicine. Jul 24 2006;166(14):1483–1489
  25. Ewertz M. Influence of non-contraceptive exogenous and endogenous sex hormones on breast cancer risk in Denmark. International Journal of Cancer. Dec 15 1988;42(6):832–838
  26. van den Brandt PA, Spiegelman D, Yaun SS, et al. Pooled analysis of prospective cohort studies on height, weight, and breast cancer risk. American Journal of Epidemiology. Sep 15 2000;152(6):514–527
  27. Lahmann PH, Hoffmann K, Allen N, et al. Body size and breast cancer risk: findings from the European Prospective Investigation into Cancer And Nutrition (EPIC). International Journal of Cancer. Sep 20 2004;111(5):762–771
  28. Eliassen AH, Colditz GA, Rosner B, et al. Adult weight change and risk of postmenopausal breast cancer. The Journal of the American Medical Association. Jul 12 2006;296(2):193–201
  29. Key TJ, Appleby PN, Reeves GK, et al. Body mass index, serum sex hormones, and breast cancer risk in postmenopausal women. Journal of the National Cancer Institute. Aug 20 2003;95(16):1218–1226
  30. Lukanova A, Lundin E, Zeleniuch-Jacquotte A, et al. Body mass index, circulating levels of sex-steroid hormones, IGF-I and IGF-binding protein-3: a cross-sectional study in healthy women. European Journal of Endocrinology. Feb 2004;150(2):161–171
  31. Cauley JA, Lucas FL, Kuller LH, et al. Study of Osteoporotic Fractures Research Group Bone mineral density and risk of breast cancer in older women: the study of osteoporotic fractures. [see comments] The Journal of the American Medical Association. 1996;276(17):1404–1408
  32. Zhang Y, Kiel DP, Kreger BE, et al. Bone mass and the risk of breast cancer among postmenopausal women. The New England Journal of Medicine. Feb 27 1997;336(9):611–617
  33. Kerlikowske K, Shepherd J, Creasman J, et al. Are breast density and bone mineral density independent risk factors for breast cancer?. Journal of the National Cancer Institute. Mar 2 2005;97(5):368–374
  34. Wang S, Paris F, Sultan CS, et al. Recombinant cell ultrasensitive bioassay for measurement of estrogens in postmenopausal women. The Journal of Clinical Endocrinology and Metabolism. Mar 2005;90(3):1407–1413
  35. Lippman ME, Krueger KA, Eckert S, et al. Indicators of lifetime estrogen exposure: effect on breast cancer incidence and interaction with raloxifene therapy in the multiple outcomes of raloxifene evaluation study participants. Journal of Clinical Oncology. Jun 15 2001;19(12):3111–3116
  36. Key T, Appleby P, Barnes I, et al. Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies. Journal of the National Cancer Institute. Apr 17 2002;94(8):606–616
  37. Missmer SA, Eliassen AH, Barbieri RL, et al. Endogenous estrogen, androgen, and progesterone concentrations and breast cancer risk among postmenopausal women. Journal of the National Cancer Institute. Dec 15 2004;96(24):1856–1865
  38. Kaaks R, Rinaldi S, Key TJ, et al. Postmenopausal serum androgens, oestrogens and breast cancer risk: the European prospective investigation into cancer and nutrition. Endocrine-Related Cancer. Dec 2005;12(4):1071–1082
  39. Hankinson SE, Manson JE, Spiegelman D, et al. Reproducibility of plasma hormone levels in postmenopausal women over a 2-3-year period. Cancer Epidemiology, Biomarkers & Prevention. 1995;4(6):649–654
  40. Kaaks R, Berrino F, Key T, et al. Serum sex steroids in premenopausal women and breast cancer risk within the European Prospective Investigation into Cancer and Nutrition (EPIC). Journal of the National Cancer Institute. May 18 2005;97(10):755–765
  41. Eliassen AH, Missmer SA, Tworoger SS, et al. Endogenous steroid hormone concentrations and risk of breast cancer among premenopausal women. Journal of the National Cancer Institute. Oct 4 2006;98(19):1406–1415
  42. Costantino JP, Gail MH, Pee D, et al. Validation studies for models projecting the risk of invasive and total breast cancer incidence. Journal of the National Cancer Institute. 1999;91(18):1541–1548
  43. Eliassen AH, Missmer SA, Tworoger SS, et al. Endogenous steroid hormone concentrations and risk of breast cancer: does the association vary by a woman's predicted breast cancer risk?. Journal of Clinical Oncology. Apr 20 2006;24(12):1823–1830
  44. Cuzick J, Powles T, Veronesi U, et al. Overview of the main outcomes in breast-cancer prevention trials. Lancet. 2003;361(9354):296–300
  45. Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. Journal of the National Cancer Institute. Nov 16 2005;97(22):1652–1662
  46. Vogel VG, Costantino JP, Wickerham DL, et al. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP study of tamoxifen and raloxifene (STAR) P-2 trial. The Journal of the American Medical Association. Jun 21 2006;295(23):2727–2741
  47. Cummings SR, Duong T, Kenyon E, et al. Serum estradiol level and risk of breast cancer during treatment with raloxifene. The Journal of the American Medical Association. Jan 9 2002;287(2):216–220
  48. Beattie MS, Costantino JP, Cummings SR, et al. Endogenous sex hormones, breast cancer risk, and tamoxifen response: an ancillary study in the NSABP Breast Cancer Prevention Trial (P-1). Journal of the National Cancer Institute. Jan 18 2006;98(2):110–115
  49. Kuiper GG, Carlsson B, Grandien K, et al. Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors alpha and beta. Endocrinology. Mar 1997;138(3):863–870
  50. Blankenstein MA, van de Ven J, Maitimu-Smeele I, et al. Intratumoral levels of estrogens in breast cancer. The Journal of Steroid Biochemistry and Molecular Biology. Apr–Jun 1999;69(1–6):293–297
  51. Geisler J. Breast cancer tissue estrogens and their manipulation with aromatase inhibitors and inactivators. The Journal of Steroid Biochemistry and Molecular Biology. Sep 2003;86(3–5):245–253
  52. Kendall A, Folkerd EJ, Dowsett M. Influences on circulating oestrogens in postmenopausal women: relationship with breast cancer. The Journal of Steroid Biochemistry and Molecular Biology. Feb 2007;103(2):99–109

PII: S1521-690X(08)00087-0

doi: 10.1016/j.beem.2008.08.001

Best Practice & Research Clinical Endocrinology & Metabolism
Volume 22, Issue 4 , Pages 573-585 , August 2008

Article Tools

* Image Usage & Resolution